TY - JOUR T1 - Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis JF - Anticancer Research JO - Anticancer Res SP - 3387 LP - 3393 DO - 10.21873/anticanres.14322 VL - 40 IS - 6 AU - ALESSANDRO MARCHIONNI AU - ISABELLA PALUMBO AU - GIAMPAOLO MONTESI AU - VITTORIO BINI AU - CLAUDIO ZUCCHETTI AU - NUNZIA CENCI AU - PIETRO CHIARINI AU - STEFANO SACCIA AU - CYNTHIA ARISTEI AU - MARCO LUPATTELLI Y1 - 2020/06/01 UR - http://ar.iiarjournals.org/content/40/6/3387.abstract N2 - Aim: To retrospectively assess toxicity and survival in 15 selected Glioblastoma patients treated with a sequential fractionated stereotactic radiotherapy (FSRT) boost after chemo-radiotherapy (CHT-RT) and compare their survival outcomes with a control group. Patients and Methods: Toxicity was assessed with the CTCAE 3.0 scale. The Kaplan-Meier method was used to design survival curves, log-rank test for bivariate analysis and Cox proportional hazard regression model for multivariate analysis. Results: The median follow-up was 16 months (range=5-60). One case of headache and one of radionecrosis (RN) occurred. Median overall survival (OS) was 25 months in the boost group vs. 14 in the no-boost group (p=0.004). Median progression-free survival (PFS) was 15 months in the boost group versus 8 in the no-boost group (p=0.046). At multivariate analysis FSRT boost resulted significantly associated with OS and PFS. Conclusion: In our series a sequential FSRT boost resulted in safe outcomes and significantly associated with survival. ER -